Joseph Burnett Sells 2,943 Shares of ClearPoint Neuro (NASDAQ:CLPT) Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) CEO Joseph Burnett sold 2,943 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $15.57, for a total value of $45,822.51. Following the sale, the chief executive officer directly owned 214,116 shares of the company’s stock, valued at approximately $3,333,786.12. The trade was a 1.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Joseph Burnett also recently made the following trade(s):

• On Friday, January 9th, Joseph Burnett sold 20,000 shares of ClearPoint Neuro stock. The shares were sold at an average price of $16.12, for a total transaction of $322,400.00.

ClearPoint Neuro Stock Down 6.7%

ClearPoint Neuro stock opened at $13.43 on Thursday. The company has a 50 day moving average of $14.14 and a 200-day moving average of $15.23. The company has a quick ratio of 5.56, a current ratio of 6.37 and a debt-to-equity ratio of 1.84. ClearPoint Neuro, Inc. has a twelve month low of $9.76 and a twelve month high of $30.10. The stock has a market capitalization of $381.68 million, a PE ratio of -15.99 and a beta of 0.91.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $5.36 million during the quarter, compared to the consensus estimate of $9.60 million. ClearPoint Neuro had a negative net margin of 67.40% and a negative return on equity of 114.28%. On average, equities research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Millennium Management LLC increased its position in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after purchasing an additional 452,043 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of ClearPoint Neuro by 98.3% in the first quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company’s stock valued at $3,066,000 after buying an additional 127,823 shares in the last quarter. Parsons Capital Management Inc. RI increased its holdings in ClearPoint Neuro by 0.7% during the second quarter. Parsons Capital Management Inc. RI now owns 143,486 shares of the company’s stock worth $1,713,000 after buying an additional 950 shares during the last quarter. MGO One Seven LLC raised its position in ClearPoint Neuro by 9.6% during the second quarter. MGO One Seven LLC now owns 17,949 shares of the company’s stock worth $214,000 after acquiring an additional 1,569 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in ClearPoint Neuro by 433.5% in the second quarter. AlphaQuest LLC now owns 9,411 shares of the company’s stock valued at $112,000 after acquiring an additional 7,647 shares during the last quarter. 30.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CLPT. Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Wednesday, January 21st. Wall Street Zen downgraded shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $9.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.